Propeller Health has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to connect patients using a Symbicort Inhaler to its digital health platform, the company announced today.

According to a release, the sensor, which was part of the 510(k) clearance, was developed in partnership with AstraZeneca, a global, science-led biopharmaceutical business.

“Our partnership with AstraZeneca will give respiratory patients a tool to help manage their condition and increase their medication adherence, a critical factor in keeping people out of the hospital,” Propeller Health CEO David Van Sickle said in a statement.

Propeller’s platform is already used in inhalers manufactured by Boehringer Ingelheim, GlaxoSmithKline, Novartis and Orion.